Ardelyx to Report First Quarter 2026 Financial Results on April 30, 2026
Rhea-AI Summary
Ardelyx (Nasdaq: ARDX) will report first quarter 2026 financial results on April 30, 2026 and host a webcast and conference call at 4:30 p.m. Eastern Time. The live webcast, slides and an archived replay will be available in the Investors "Events and Presentations" section at www.ardelyx.com.
Positive
- None.
Negative
- None.
News Market Reaction – ARDX
In the Apr 16 session, ARDX declined 0.32%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Earnings date Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 05 | Earnings date notice | Neutral | -5.2% | Scheduled full year and Q4 2025 results call with business update. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Prior earnings-date scheduling news was followed by a -5.15% move, suggesting a tendency for modest downside around such announcements.
Ardelyx has established a pattern of announcing earnings dates with post-close conference calls. On Feb 5, 2026, the company set a call for Feb 19, 2026 at 4:30 p.m. ET to review full year and Q4 2025 results and provide a business update. That earnings-date announcement coincided with a -5.15% one-day move, framing how the stock has historically traded around similar scheduling news.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Conference call scheduled for 4:30 p.m. Eastern Time
WALTHAM, Mass., April 16, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX) (“Ardelyx” or the “Company”), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today announced that management will host a webcast and conference call on Thursday, April 30, 2026, at 4:30 p.m. Eastern Time to discuss financial results and provide a business update from the first quarter of 2026.
Webcast Information
A live webcast of the conference call and accompanying slides will be available in the “Events and Presentations” section under “News and Events” within the Investors section of the Company’s website at www.ardelyx.com.
An archived replay of the webcast and related presentation materials will be available on the Company’s website following the event.
Conference Call Details
Domestic (toll-free): 877-346-6112
International (toll): +1 848-280-6350
About Ardelyx
Ardelyx is a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs. Ardelyx has two commercial products approved in the United States, IBSRELA® (tenapanor) and XPHOZAH® (tenapanor). The company’s pipeline includes the Phase 3 development of IBSRELA for chronic idiopathic constipation (CIC) and RDX10531, a next-generation NHE3 inhibitor with potential application across multiple therapeutic areas. Ardelyx works with its partners to develop and commercialize its products outside of the United States. For more information, please visit https://ardelyx.com/ and connect with us on X (formerly known as Twitter), LinkedIn and Facebook.
Investor Contact:
Lisa Caperelli
lcaperelli@ardelyx.com
